# A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

> **NCT04172597** · PHASE2 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 1 (actual)

## Conditions studied

- Breast Cancer
- Colorectal Cancer
- Solid Tumor
- Glioblastome Multiforme

## Interventions

- **DRUG:** Poziotinib Hydrochloride
- **DRUG:** Loperamide

## Key facts

- **NCT ID:** NCT04172597
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-23
- **Primary completion:** 2022-03-29
- **Final completion:** 2022-03-29
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Strategic business decision (unrelated to safety)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04172597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04172597, "A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04172597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*